US20180186894A1 - Targeted modified il-1 family members - Google Patents
Targeted modified il-1 family members Download PDFInfo
- Publication number
- US20180186894A1 US20180186894A1 US15/901,545 US201815901545A US2018186894A1 US 20180186894 A1 US20180186894 A1 US 20180186894A1 US 201815901545 A US201815901545 A US 201815901545A US 2018186894 A1 US2018186894 A1 US 2018186894A1
- Authority
- US
- United States
- Prior art keywords
- cells
- targeting
- mutant
- cytokine
- nanobody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000008685 targeting Effects 0.000 claims abstract description 73
- 102000039996 IL-1 family Human genes 0.000 claims abstract description 50
- 108091069196 IL-1 family Proteins 0.000 claims abstract description 50
- 102000004127 Cytokines Human genes 0.000 claims abstract description 49
- 108090000695 Cytokines Proteins 0.000 claims abstract description 49
- 230000002829 reductive effect Effects 0.000 claims abstract description 16
- 102000003675 cytokine receptors Human genes 0.000 claims abstract description 5
- 108010057085 cytokine receptors Proteins 0.000 claims abstract description 5
- 102000005962 receptors Human genes 0.000 claims description 20
- 108020003175 receptors Proteins 0.000 claims description 20
- 101150029707 ERBB2 gene Proteins 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 39
- 230000004927 fusion Effects 0.000 abstract description 33
- 102000000589 Interleukin-1 Human genes 0.000 abstract description 29
- 108010002352 Interleukin-1 Proteins 0.000 abstract description 29
- 102000019223 Interleukin-1 receptor Human genes 0.000 abstract description 4
- 108050006617 Interleukin-1 receptor Proteins 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 71
- 230000004071 biological effect Effects 0.000 description 20
- 230000027455 binding Effects 0.000 description 16
- 108020001507 fusion proteins Proteins 0.000 description 15
- 102000037865 fusion proteins Human genes 0.000 description 15
- 102000003810 Interleukin-18 Human genes 0.000 description 14
- 108090000171 Interleukin-18 Proteins 0.000 description 14
- 108010057466 NF-kappa B Proteins 0.000 description 14
- 102000003945 NF-kappa B Human genes 0.000 description 14
- 230000004913 activation Effects 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 230000035772 mutation Effects 0.000 description 10
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 102100033500 Interleukin-33 Human genes 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 108010067003 Interleukin-33 Proteins 0.000 description 7
- 241000588832 Bordetella pertussis Species 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 102000013691 Interleukin-17 Human genes 0.000 description 5
- 108050003558 Interleukin-17 Proteins 0.000 description 5
- 210000000068 Th17 cell Anatomy 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 5
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 230000005937 nuclear translocation Effects 0.000 description 5
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 102100021150 Interleukin-36 receptor antagonist protein Human genes 0.000 description 3
- 101710089409 Interleukin-36 receptor antagonist protein Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001085 cytostatic effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 102000005861 leptin receptors Human genes 0.000 description 3
- 108010019813 leptin receptors Proteins 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 2
- 101000998122 Homo sapiens Interleukin-37 Proteins 0.000 description 2
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 2
- -1 IL-36α Proteins 0.000 description 2
- 108010057368 Interleukin-1 Type I Receptors Proteins 0.000 description 2
- 102100026015 Interleukin-1 family member 10 Human genes 0.000 description 2
- 102100039880 Interleukin-1 receptor accessory protein Human genes 0.000 description 2
- 101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 description 2
- 102100026016 Interleukin-1 receptor type 1 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102100033502 Interleukin-37 Human genes 0.000 description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 210000000447 Th1 cell Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229960001714 calcium phosphate Drugs 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000005860 defense response to virus Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical class NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 239000001987 Bordet-Gengou agar Substances 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010025905 Cystine-Knot Miniproteins Proteins 0.000 description 1
- 101710154643 Filamentous hemagglutinin Proteins 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical group C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 1
- 101000998137 Homo sapiens Interleukin-33 Proteins 0.000 description 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 229940099539 IL-36 receptor antagonist Drugs 0.000 description 1
- 108010034143 Inflammasomes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108050004799 Interleukin-1 family member 10 Proteins 0.000 description 1
- 102100036706 Interleukin-1 receptor-like 1 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102100033474 Interleukin-36 alpha Human genes 0.000 description 1
- 108050004801 Interleukin-36 alpha Proteins 0.000 description 1
- 102100033498 Interleukin-36 beta Human genes 0.000 description 1
- 108050003379 Interleukin-36 beta Proteins 0.000 description 1
- 102100033503 Interleukin-36 gamma Human genes 0.000 description 1
- 101710195086 Interleukin-36 gamma Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 101150053046 MYD88 gene Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 description 1
- 108010047562 NGR peptide Proteins 0.000 description 1
- 101150003511 NR3C2 gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 102000005747 Transcription Factor RelA Human genes 0.000 description 1
- 108010031154 Transcription Factor RelA Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229940124832 acellular pertussis vaccine Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000043959 human IL18 Human genes 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000024949 interleukin-17 production Effects 0.000 description 1
- 230000031037 interleukin-18 production Effects 0.000 description 1
- 102000008625 interleukin-18 receptor activity proteins Human genes 0.000 description 1
- 108040002014 interleukin-18 receptor activity proteins Proteins 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000000503 lectinlike effect Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
- The present invention relates to a modified Interleukin-1 (IL-1) family member cytokine, with reduced activity via its cytokine receptor, wherein said Interleukin-1 family member cytokine is specifically delivered to target cells. Preferably, the IL-1 family member cytokine is a mutant, more preferably it is a mutant IL-1 with low affinity to the IL-1 receptor, wherein said mutant IL-1 is specifically delivered to target cells. The targeting is preferably realized by fusion of the modified IL-1 family member cytokine to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified IL-1 family member cytokine to treat diseases.
- The Interleukin-1 (IL-1) family consists of 11 structurally related family members (IL-1α, IL-1-β, IL-1Ra, IL-18, IL-33 and IL-1F5 to IL-1 F10), that are among the most potent immune system signaling molecules, acting through a group of closely related receptors. All IL-1 receptors have a similar mode of activation: upon binding of ligand to the primary receptor subunit (i.e. IL-1R1 for IL-1α and β, IL-18R for IL-18 and ST2 for IL-33), a second receptor subunit is recruited (i.e. IL-1RAP for IL-1α and β, IL-18RAP for IL-18 and IL-1RAP for IL-33) and signalling is initiated via juxtaposition of the receptor subunits' cytoplasmic Toll/IL-1 receptor (TIR) domains. The dimerized TIR domains provide a docking platform for the MYD88 adaptor protein, which via recruitment of other intermediates leads to activation of the pro-inflammatory nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) pathways. The IL-1 family members are primarily produced by innate immune cells and act on a variety of cell types during the immune response (for review see Sims and Smith, 2010).
- T lymphocytes are one of the main IL-1 family target cells and the potentiating effects of in particular IL-1α and IL-1β on the expansion and differentiation of different T cell subsets, in particular CD8+ T cells (Ben-Sasson, 2011; Ben-Sasson, 2013) and Th17 cells (Sutton et al., 2006; Acosta-Rodriguez et al., 2007; Dunne et al., 2010; Shaw et al., 2012) have been firmly established. Th17 cells are characterized by the production of IL-17 and play an important role in auto-immune disease and chronic inflammation (reviewed in Wilke et al., 2011). Among T cell subsets, Th17 cells express the highest levels of the IL-1R and IL-1 plays an important role in Th17 priming.
- IL-18 is best known as an IFNγ-inducing cytokine with a potent action on Th1 cells and natural killer (NK) cells, on (Okamura et al., 1995; Takeda et al. 1998). In addition, IL-18 enhances neutrophil function (Leung et al., 2001). Several reports demonstrate IL-18 anti-tumour action in animal models (Micallef et al., 1997; Loeffler et al., 2008; Wigginton et al., 2002; Zaki et al., 2010) and recombinant human IL-18 therapy recently entered clinical trials to evaluate its efficacy for treatment of advanced cancer (Robertson et al., 2008). As opposed to IL-18, IL-33 acts primarily on Th2 cells (Schmitz et al., 2005) and mast cells (Allakhverdi et al., 2007), and recently was shown to act on CD8+T cells to drive antiviral responses (Bonilla et al., 2012). The other IL-1 family members are less well characterized, but in summary different IL-1 family members have specificities for different T-cell subsets or other cell types and hence different therapeutic applications.
- Besides having indirect anti-tumour activity, via activation of T and NK cells, IL-1 family members were shown to have direct cytostatic properties, which were most convincingly demonstrated on human melanoma cells (Morinaga et al., 1990; Usui et al., 1991; Rangnekar et al., 1992).
- In view of the contribution of several IL-1 family members to inflammatory processes, clinical interest has been mainly oriented towards the development of IL-1-antagonizing strategies (Dinarello et al., 2012). Nevertheless, exploitation of controlled agonistic IL-1 activity could have applications in different physiological/pathological processes, where immunostimulatory effects would be desirable. One of the main concerns regarding the use of IL-1 in immunostimulatory therapies, is its severe toxicity when administered systemically. However, when IL-1 action could be confined to a selected cellular population, the toxicity issue might be resolved, which opens up therapeutic perspectives.
- For instance, although there has been a lot of interest on blocking Th17 responses in view of their pathogenic role in auto-immune conditions such as multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease (Wilke et al., 2011), normal Th17 function is indispensable for protective immunity against a range of pathogens, including Mycobacterium tuberculosis (Khader et al., 2007), Klebsiella pneumoniae (Ye et al., 2001) and Bordetella pertussis (Higgins et al., 2006). As IL-1β stimulates Th17 function, the idea has been raised to use IL-1β as a T-cell adjuvant to enhance the response to weak vaccines (Ben-Sasson et al., 2011). Other applications could be the targeting of IL-1β or IL-33 to the CD8+ T-cell population to enhance antiviral responses or targeting IL-18 to Th1 cells or NK cells to promote anti-tumor activity.
- Surprisingly we found that it is possible to design IL-1 family modifications that are defective in activating their receptor, but, when fused to a targeting moiety, regain their activity on selected cell types by a concentration effect at the cell surface. The IL-1 mutants have a reduced affinity for their cognate receptors, and hence are unable to efficiently bind and activate their receptors. However, by fusing them to a targeting moiety (such as a nanobody) the activity of the mutant IL-1 family member is restored on cells expressing the cell surface target, recognized by the targeting moiety. Because the activation is confined to the selected targeted cell types only, no major systemic toxicity occurs.
- A first aspect of the invention is a targeting construct, comprising a modified IL-1 family member cytokine, characterized by a reduced affinity for its cytokine receptor, and a targeting moiety. IL-1 family member cytokines are known to the person skilled in the art, and include, but are not limited to IL-1α, IL-1β, IL-1Ra, IL18, IL-36Ra, IL-36α, IL-37, IL-36β, IL-36γ, IL-38 and IL-33 (also indicated as IL-1F1, IL-1F2, IL-1F3, IL-1F4, IL-1F5, IL-1F6, IL-1F7, IL-1F8, IL-1F9, IL-1F10 and IL-1F11, respectively). Fora review on the IL-1 family, see Dinarello (2011). A modified IL-1 family cytokine means that the IL-1 family cytokine has been changed to alter the affinity to its receptor, with as final result that the modified IL-1 family cytokine has a reduced affinity for the receptor and a consequent reduced biological activity, as compared to the endogenous wild type cytokine that binds normally to the receptor. Such a modification can be a modification that decreases the activity of the normal wild type cytokine, or it can be a modification that increases the affinity of a homologous, non-endogenous IL-1 family cytokine (such as, but not limited to a IL-1 family cytokine of another species that is not active on a human IL-1 family cytokine receptor). Modifications can be any modification reducing or increasing the activity, known to the person skilled in the art, including but not limited to chemical and/or enzymatic modifications such as pegylation and glycosylation, fusion to other proteins and mutations. Preferably said modification is a mutation, even more preferably it is a mutation decreasing the affinity of the IL-1 family cytokine. A reduced affinity and a consequent reduced biological activity as used here means that the modified IL-1 family cytokine has a biological activity of less than 70% of the biological activity of the IL-1 family cytokine, even more preferably less than 60% of the biological activity of the IL-1 family cytokine, more preferably less than 50% of the biological activity of the IL-1 family cytokine, more preferably less than 40% of the biological activity of the IL-1 family cytokine, more preferably less than 30% of the biological activity of the IL-1 family cytokine, more preferably less than 20% of the biological activity of the IL-1 family cytokine, more preferably less than 10% of the biological activity of the IL-1 family cytokine, most preferably less than 1% of the biological activity of the IL-1 family cytokine as compared to the IL-1 family cytokine that normally binds to the receptor. Preferably, the modified IL-1 family cytokine is a mutant of the wild type IL-1 family cytokine and the activity is compared with the wild type IL-1 family cytokine. The affinity and/or the activity can be measured by any method known to the person skilled in the art.
- A preferred embodiment of the invention is a targeting construct, comprising a mutant IL-1β characterized by reduced affinity for the Interleukin-1 receptor type I (IL-1RI) and/or the interleukin-1 receptor accessory protein (IL-1RAcP) receptor, and a targeting moiety. A mutant IL-1β as used here can be any mutant form that has a lower affinity for the receptor and as a consequence a reduced activation of the proinflammatory transcription factor NFκB. The affinity of the mutant IL-1β to the receptor, in comparison to the affinity of the wild type IL-1β to the receptor can be measured by Scatchard plot analysis and computer-fitting of binding data (e.g. Scatchard, 1949) or by reflectometric interference spectroscopy under flow through conditions, as described by Brecht et al. (1993). The activity of the mutant IL-1β is typically measured using a bioassay (for example by the induction of cell death) or by measuring signaling events downstream of the receptor. Such signaling events can be the modification or nuclear translocation of NF-κB, or the induction of a selected reporter gene. The mutant may be a point mutant, a deletion or an insertion mutant, or a combination thereof; several mutations may be present in one protein. Preferably, said mutant IL-1β is obtained by active mutagenesis, such as, but not limited to site directed mutagenesis by polymerase chain reaction amplification. Preferably, said mutant IL-1β has a biological activity of less than 70% of the biological activity of the wild type IL-1β, even more preferably less than 60% of the biological activity of the wild type IL-1β, more preferably less than 50% of the biological activity of the wild IL-1β, more preferably less than 40% of the biological activity of the wild IL-1β, more preferably less than 30% of the biological activity of the wild IL-1β, more preferably less than 20% of the biological activity of the wild IL-1β, more preferably less than 10% of the biological activity of the wild type, most preferably less than 1% of the wild type of which it is deduced (i.e. the wild type IL-1β of which the coding sequence has been mutated to obtain the mutant IL-1β). Preferably, said mutant is a mutant selected from the group consisting of A117G/P118G, R120X, L122A, T125G/L126G, R127G, Q130X, Q131G, K132A, S137G/Q138Y, L145G, H146X, L145A/L147A, Q148X, Q148G/Q150G, Q150G/D151A, M152G, F162A, F162A/Q164E, F166A, Q164E/E167K, N169G/D170G, 1172A, V174A, K208E, K209X, K209A/K210A, K219X, E221X, E221S/N224A, N224S/K225S, E244K, N245Q (wherein X can be any change in amino acid, preferably a non-conservative change). Even more preferably said mutation is selected from the group consisting of R120A, R120G, Q130A, Q130W, H146A, H146G, H146E, H146N, H146R, Q148E, Q148G, Q148L, K209A, K209D, K219S, K219Q, E221S and E221K. Most preferably said mutation is selected from the group consisting of R120G, H146N, H146R, Q148E, Q148G and K209A. (numbering base on the human IL-1(3 sequence, genbank accession number NP_000567, version NP-000567.1, GI: 10835145).
- Preferred regions for mutations for IL-18 are Y37-K44, R49-Q54, D59-R63, E67-C74, R80, M87-A97, N127-K129, Q139-M149, K165-K171, R183 and Q190-N191. Most preferred are the regions E67-C74 and M87-A97 (numbering based on the human sequence, genbank accession number AAV38697, version AAV38697.1, GI: 54696650) .
- Preferred regions for mutations for IL-33 are I113-Y122, S127-E139, E144-D157, Y163-M183, E200, Q215, L220-C227 and T260-E269 (numbering based on the human sequence, genbank accession number NP_254274, version NP_254274.1, GI:15559209)
- Preferably, said targeting moiety is targeting to a marker expressed on an IL-1β receptor expressing cell, preferably a cell expressing IL1-RI. In one preferred embodiment, said targeting moiety is directed to a tissue specific marker.
- The modified IL-1 family member is linked to a targeting moiety. “Linked” as used here may be by a covalent binding, or it may be by an affinity binding. A “targeting moiety” as used here is a binding molecule that can direct the fusion protein towards a binding site on a cell that is expressing a receptor for the IL-1 family member, by specific interaction between the binding site and the binding molecule. In one preferred embodiment, said binding molecule is a small compound, specifically binding to a molecule situated on the outside of the cell. In another preferred embodiment, said molecule is a sugar structure, directed towards a lectin-like molecule expressed on the cell wall. In another preferred embodiment said binding molecule is a peptide, targeting the tumor or inflammation environment. Such peptides are known to the person skilled in the art, and include, but are not limited to NGR and RGD peptides (Yang et al., 2011; WO2005054293). In still another preferred embodiment, said binding molecule is a protein comprising a binding domain. This includes, but is not limited to carbohydrate binding domains (CBD) (Blake et al, 2006), lectin binding proteins, heavy chain antibodies (hcAb), single domain antibodies (sdAb), minibodies (Tramontano et al., 1994), the variable domain of camelid heavy chain antibodies (VHH), the variable domain of the new antigen receptors (VNAR), affibodies (Nygren et al., 2008), alphabodies (WO2010066740), designed ankyrin-repeat domains (DARPins) (Stumpp et al., 2008), anticalins (Skerra et al., 2008), knottins (Kolmar et al., 2008) and engineered CH2 domains (nanoantibodies; Dimitrov, 2009). Preferably, said targeting moiety consists of a single polypeptide chain and is not post-translationally modified. Even more preferably, said targeting moiety is a nanobody.
- The targeting moiety can be any targeting moiety known to the person skilled in the art. In a non-limiting example, said targeting moiety may be a bispecific antibody, directed to a binding site on the target cell for one specificity, and to the targeted cytokine, or to a tag fused to said cytokine for the other specificity. In another non-limiting example, the targeting moiety may be chemically linked to the mutant Interleukin-1, or it may be a recombinant fusion protein. Preferably, said targeting construct is a recombinant fusion protein. The targeting moiety may be fused directly to the mutant IL-1β, or it may be fused with the help of a linker fragment, preferably a GGS linker. The targeting moiety may be fused at the aminoterminal or at the carboxyterminal end of the mutated IL-1β; preferably said targeting moiety is fused at the carboxyterminal extremity of the mutated IL-1β molecule. The targeting construct may further comprise other domains such as, but not limited to a tag sequence, a signal sequence, another cytokine or an antibody.
- Another aspect of the invention is a targeting construct according to the invention for use as a medicament. One preferred embodiment is a targeting construct according to the invention for use in stimulation of the immune response. Indeed, it is know that IL-1 treatment can induce antigen expression on B-cells (Killer et al., 1989); likewise, IL-18 treatment is augmenting cellular and humoral immunities (Kinoshita et al., 2011). In a similar way, it has been demonstrated that IL-1 acts on T-cells to enhance the magnitude of in vivo immune responses (Ben-Sasson et al., 2011; Ben Sasson et al., 2013). Therefore, one preferred aspect of the invention is the targeting construct according to the invention for use as an adjuvant in vaccination. The targeting construct according to the invention is especially interesting in this respect, as the pro-inflammatory effect of normal wild type IL-1 makes the application of IL-1 as such impossible.
- Still another aspect of the invention is a targeting construct according to the invention for use in treatment of cancer. Indeed, Morinaga et al., 1990, Usui et al., 1991and Rangnekar et al., 1992 have shown that IL-1 family members do have direct cytostatic properties, which were most convincingly demonstrated on human melanoma cells.
-
FIG. 1 : Schematic representation of the IL-1β-nanobody fusion proteins -
FIG. 2 : Concentration dependency of the induction of the NFκB activity by wild type and mutant Q148G IL-1 Her2 nanobody fusions (A) and other selected mutants (B), in mock transfected cells, or cells transfected with signaling deficient Her2. -
FIG. 3 : Effect of wild type and mutant (Q148G, L145A/L147A, F162A/Q164E) IL-1 Her2 nanobody fusions on nuclear translocation of endogenous NF-κB p65 in mock transfected cells, or cells transfected with signaling deficient Her2. -
FIG. 4 : Induction of the NFκB activity by wild type and 5 different IL-1 mutants, fused to an anti-murine leptin receptor nanobody, on cells expressing the murine leptin receptor (mLR) or not (no mLR). -
FIG. 5 : Concentration dependency of the induction of the NFκB activity by ILA double mutants fused to the Her2 nanobody in mock transfected cells, or cells transfected with signaling deficient Her2. - Materials and Methods to the Examples
- Cloning of IL-1-Nanobody Fusion Proteins.
- The 4-10 nanobody directed against the murine leptin receptor is described in Zabeau et al. (2012) and in the patent WO 2006/053883. The anti-Her2 nanobody 1R59B is described in Vaneycken et al. (2011). Both nanobodies were cloned with a C-terminal His tag in the pMET7 eukaryotic expression vector. A codon-optimized sequence encoding the mature IL-1β protein, preceded by the SigK leader peptide, and equipped with an N-terminal HA tag, was generated via gene synthesis (Invitrogen Gene Art). To generate the IL-1β-nanobody fusion proteins, the IL-1β sequence was cloned 5′ to the nanobody sequence in pMet7, with a 13×GGS linker separating the cytokine and nanobody moieties. (
FIG. 1 ) - IL-1β Mutants.
- IL-1β mutants expected to have reduced binding affinity for the IL-1R were selected based on literature and analysis of published crystal structures of human IL-1β complexed with its receptor. Mutations in the hIL-1β moiety were created via site-directed mutagenesis (QuickChange, Stratagene) using the mutagenesis primers as indicated in table I:
-
TABLE I mutants and primers used Fw primer Rev primer 1 A117G/ CCGACTACGCTGGCGGCAGTGACGGTGTCA GCAGTTCAGGCTTCTGACACCGTCACTG P118G GAAGCCTGAACTGC CCGCCAGCGTAGTCGG 2 R120A CTGGCGGCAGCGCCCCTGTCGCTAGCCTGA CGCAGGGTGCAGTTCAGGCTAGCGACA ACTGCACCCTGCG GGGGCGCTGCCGCCAG 3 R120G GCGGCAGCGCCCCTGTCGGAAGCTTGAACT GCAGGGTGCAGTTCAAGCTTCCGACAG GCACCCTGC GGGCGCTGCCGC 4 L122A CGCTGGCGGCAGTGCCCCTGTCAGAAGCGC GCTGTCCCGCAGGGTGCAGTTCGCGCT GAACTGCACCCTGCGGGACAGC TCTGACAGGGGCACTGCCGCCAGCG 5 T125G/ CGCCCCTGTCAGAAGCCTGAACTGCGGCGG GCTTTTCTGCTGGCTGTCCCGGCCGCC L126 GCCGGGACAGCCAGCAGAAAAGC GCAGTTCAGGCTTCTGACAGGGGCG 6 R127G AGAAGCCTGAACTGCACACTGGGGGACAGC GACCAGGCTTTTCTGCTGGCTGTCCCCC CAGCAGAAAAGCCTGGTC AGTGTGCAGTTCAGGCTTCT 7 Q130A CCCTGCGGGACAGCGCGCAGAAAAGCCTGG CCAGGCTTTTCTGCGCGCTGTCCCGCA GGG 8 Q130W CTGCACCCTGCGGGACAGCTGGCAGAAAAG GCTCATGACCAGGCTTTTCTGCCAGCTG CCTGGTCATGAGC TCCCGCAGGGTGCAG 9 Q131G CTGCGGGACAGCCAGGGGAAGAGCCTGGTC CGCTCATGACCAGGCTCTTCCCCTGGCT ATGAGCG GTCCCGCAG 10 K132A GCACCCTGCGGGACAGCCAGCAGGCTAGCC GGCCGCTCATGACCAGGCTAGCCTGCT TGGTCATGAGCGGCC GGCTGTCCCGCAGGGTGC 11 S137G/ CAGCAGAAAAGCCTGGTCATGGGGTACCCCT GCAGTGCCTTCAGCTCGTAGGGGTACC Q138Y ACGAGCTGAAGGCACTGC CCATGACCAGGCTTTTCTGCTG 12 L145G GCCCCTACGAGCTGAAGGCAGGTCATCTGCA CCATGTCCTGGCCCTGCAGATGACCTG GGGCCAGGACATGG CCTTCAGCTCGTAGGGGC 13 H146A CGAGCTGAAGGCACTGGCTCTTCAGGGCCA CCATGTCCTGGCCCTGAAGAGCCAGTG GGACATGG CCTTCAGCTCG 14 H146G CCTACGAGCTGAAGGCACTGGGTCTGCAGG CCATGTCCTGGCCCTGCAGACCCAGTG GCCAGGACATGG CCTTCAGCTCGTAGG 15 M146E GCTGAAGGCACTGGAGCTGCAGGGCCAGG CCTGGCCCTGCAGCTCCAGTGCCTTCA GC 16 H146N AGCTGAAGGCACTGAATCTGCAGGGCCAG CTGGCCCTGCAGATTCAGTGCCTTCAGC T 17 H146R CTGAAGGCACTGCGTCTGCAGGGCCAG CTGGCCCTGCAGACGCAGTGCCTTCAG 18 L145A/ GCGGCCCCTACGAGCTGAAGGCAGCGCATG CCATGTCCTGGCCCTGCGCATGCGCTG L147A CGCAGGGCCAGGACATGG CCTTCAGCTCGTAGGGGCCGC 19 Q148E GGCACTGCATCTGGAGGGCCAGGACAT ATGTCCTGGCCCTCCAGATGCAGTGCC 20 Q148G GAAGGCACTGCATCTGGGTGGCCAGGACAT GCTGTTCCATGTCCTGGCCACCCAGATG GGAACAGC CAGTGCCTTC 21 Q148L GCACTGCATCTGCTGGGCCAGGACATG CATGTCCTGGCCCAGCAGATGCAGTGC 22 Q148G/ CGAGCTGAAGGCACTGCATCTGGGGGGCGG CCTGCTGTTCCATGTCCCCGCCCCCCA Q150G GGACATGGAACAGCAGG GATGCAGTGCCTTCAGCTCG 23 Q150G/ GCACTGCATCTGCAGGGCGGGGCCATGGAA GCTGAACACGACCTGCTGTTCCATGGCC D151A CAGCAGGTCGTGTTCAGC CCGCCCTGCAGATGCAGTGC 24 M152G GCACTGCATCTGCAGGGCCAGGACGGGGAA GCTCATGCTGAACACCACCTGCTGTTCC CAGCAGGTGGTGTTCAGCATGAGC CCGTCCTGGCCCTGCAGATGCAGTGC 25 F162A CATGGAACAGCAGGTGGTGTTCAGCATGAGC GTCGTTGCTTTCCTCGCCCTGCACGGC GCCGTGCAGGGCGAGGAAAGCAACGAC GCTCATGCTGAACACCACCTGCTGTTCC ATG 26 F162A/ GCAGGTCGTGTTCAGCATGAGCGCCGTGGA GGATCTTGTCATTGCTTTCCTCGCCCTC Q164E GGGCGAGGAAAGCAATGACAAGATCC CACGGCGCTCATGCTGAACACGACCTG C 27 F166A CCGACTTCACCATGCAGGCCGTCTCCAGCGG CCAGATCTGCTGCCGCCGCTGGAGACG CGGCAGCAGATCTGG GCCTGCATGGTGAAGTCGG 28 Q164E/ GCATGAGCTTCGTGGGGGGCAAGGAAAGCA GGCCACGGGGATCTTGTCATTGCTTTCC E167K ATGACAAGATCCCCGTGGCC TTGCCCCCCACGAAGCTCATGC 29 N169G/ GCAGGGCGAGGAAAGCGGCGGCAAGATCCC CTTCTCTTTCAGGCCTAGGGCCACGGG D170G CGTGGCCCTAGGCCTGAAAGAGAAG GATCTTGCCGCCGCTTTCCTCGCCCTGC 30 I172A GAAAGCAACGACAAGGCCCCCGTGGCCCTG CCCAGGGCCACGGGGGCCTTGTCGTTG GG CTTTC 31 V174A GCAACGACAAGATCCCCGCGGCCCTGGGCC CTTTCAGGCCCAGGGCCGCGGGGATCT TGAAAG TGTCGTTGC 32 K208E GCAGCTGGAAAGCGTGGATCCCAAGAACTAC GCGTTTTTCCATCTTTTTCTCGGGGTAGT CCCGAGAAAAAGATGGAAAAACGC TCTTGGGATCCACGCTTTCCAGCTGC 33 K209A CCCCAAGAACTACCCCAAGGCAAAGATGGAA GTTGAACACGAAGCGCTTTTCCATCTTT AAGCGCTTCGTGTTCAAC GCCTTGGGGTAGTTCTTGGGG 34 K209D GCAGCTGGAAAGCGTGGATCCCAAGAACTAC GCGTTTTTCCATCTTGTCCTTGGGGTAG CCCAAGGACAAGATGGAAAAACGC TTCTTGGGATCCACGCTTTCCAGCTGC 35 K209A/ CCCCAAGAACTACCCCAAGGCAGCGATGGAA GAACACGAAGCGTTTTTCCATCGCTGCC K210A AAACGCTTCGTGTTC TTGGGGTAGTTCTTGGGG 36 K219S AAAAACGCTTCGTGTTCAACAGCATCGAGAT GAGCTTGTTGTTGATCTCGATGCTGTTG CAACAACAAGCTC AACACGAAGCGTTTTT 37 K219Q AAAAACGCTTCGTGTTCAACCAGATCGAGAT CTTGTTGTTGATCTCGATCTGGTTGAAC CAACAACAAG ACGAAGCGTTTTT 38 E221S GCTTCGTGTTCAACAAGATCTCGATCAACAAC ACTCGAGCTTGTTGTTGATCGAGATCTT AAGCTCGAGT GTTGAACACGAAGC 39 E221K CTTCGTGTTCAACAAGATCAAGATCAACAACA TCGAGCTTGTTGTTGATCTTGATCTTGTT AGCTCGA GAACACGAAG 40 K219S/ GGAAAAACGCTTCGTCTTCAACAGCATCTCG CGAACTCGAGCTTGTTGTTGATCGAGAT E221S ATCAACAACAAGCTCGAGTTCG GCTGTTGAAGACGAAGCGTTTTTCC 41 E221S/ CGCTTCGTGTTCAACAAGATCTCGATCAACG CTCGAACTCGAGCTTGGCGTTGATCGAG N224A CCAAGCTCGAGTTCGAG ATCTTGTTGAACACGAAGCG 42 N224S/ CAACAAGATCGAGATCAACAGCAGCCTCGAA CTGGGCGCTCTCGAATTCGAGGCTGCT K225S TTCGAGAGCGCCCAG GTTGATCTCGATCTTGTTG 43 E244K CCCCAACTGGTACATCAGTACTAGTCAGGCC GGAACACGGGCATATTCTTGGCCTGACT AAGAATATGCCCGTGTTCC AGTACTGATGTACCAGTTGGGG 44 N245Q CAGCACTAGTCAGGCCGAGCAGATGCCCGT GGTGCCGCCCAGGAAGACGGGCATCTG CTTCCTGGGCGGCACC CTCGGCCTGACTAGTGCTG 45 E244K/ CATCAGCACTAGTCAGGCCAAGCAGATGCCC GGTGCCGCCCAGGAAGACGGGCATCTG N245Q GTCTTCCTGGGCGGCACC CTTGGCCTGACTAGTGCTGATG 46* R120G GCGGCAGCGCCCCTGTCGGAAGCTTGAACT GCAGGGTGCAGTTCAAGCTTCCGACAG Q131G GCACCCTGC GGGCGCTGCCGC 47* R120G/ CGAGCTGAAGGCACTGGCTCTTCAGGGCCA CCATGTCCTGGCCCTGAAGAGCCAGTG H146A GGACATGG CCTTCAGCTCG 49* R120G/ GCGGCCCCTACGAGCTGAAGGCAGCGCATG CCATGTCCTGGCCCTGCGCATGCGCTG L145A/ CGCAGGGCCAGGACATGG CCTTCAGCTCGTAGGGGCCGC L147A 48** R120G/ GCGGCAGCGCCCCTGTCGGAAGCTTGAACT GCAGGGTGCAGTTCAAGCTTCCGACAG Q148G GCACCCTGC GGGCGCTGCCGC 50* R120G/ GCAGGTCGTGTTCAGCATGAGCGCCGTGGA GGATCTTGTCATTGCTTTCCTCGCCCTC F162A/ GGGCGAGGAAAGCAATGACAAGATCC CACGGCGCTCATGCTGAACACGACCTG Q164E C 51* R120G/ GCAGCTGGAAAGCGTGGATCCCAAGAACTAC GCGTTTTTCCATCTTTTTCTCGGGGTAGT K208E CCCGAGAAAAAGATGGAAAAACGC TCTTGGGATCCACGCTTTCCAGCTGC 52** Q131G/ CTGCGGGACAGCCAGGGGAAGAGCCTGGTC CGCTCATGACCAGGCTCTTCCCCTGGCT Q148G ATGAGCG GTCCCGCAG 53** Q148G/ GCAGGTCGTGTTCAGCATGAGCGCCGTGGA GGATCTTGTCATTGCTTTCCTCGCCCTC F162A/ GGGCGAGGAAAGCAATGACAAGATCC CACGGCGCTCATGCTGAACACGACCTG Q164E C 54** Q148G/ GCAGCTGGAAAGCGTGGATCCCAAGAACTAC GCGTTTTTCCATCTTTTTCTCGGGGTAGT K208E CCCGAGAAAAAGATGGAAAAACGC TCTTGGGATCCACGCTTTCCAGCTGC *double/triple-mutants were created using R120G as template. **double/triple-mutants were created using Q148G as template. - Production of IL-1β Fusion Proteins.
- IL-1β fusion proteins were produced in HEK293T cells. For small-scale production, HEK293T cells were seeded in 6-well plates at 400000 cells/well in DMEM supplemented with 10% FCS. After 24 hours, culture medium was replaced by medium with reduced serum (DMEM/5% FCS) and cells were transfected using linear PEI. Briefly, PEI transfection mix was prepared by combining 1 μg expression vector with 5 μg PEI in 160 μl DMEM, incubated for 10 minutes at RT and added to the wells dropwise. After 24 hours, transfected cells were washed with DMEM and layered with 1.5 ml OptiMem/well for protein production. Conditioned media were recuperated after 48 hours, filtered through 0.45 p filters and stored at −20° C. IL-1β content in the conditioned media was determined by Elisa according to the manufacturer's instructions (R&D Systems).
- NF-κB Reporter Gene Assay.
- To assess IL-1R activation, we used HEK-Blue™ IL-1β cells that stably express the IL-1R (Invivogen) and transfected them transiently with an NF-κB luciferase reportergene. Briefly, HEK-Blue™ IL-1β cells were seeded in culture medium (DMEM/10% FCS) in 96-well plates (10000 cells/well) and transfected the next day using the calciumphosphate precipitation method with the indicated amounts of expression plasmids and 5 ng/well of the 3κB-Luc reportergene plasmid (Vanden Berghe et al., 1998). 24 hours post-transfection, culture medium was replaced by starvation medium (DMEM) and 48 hours post-transfection, cells were induced for 6 hours with fusion proteins. After induction, cells were lysed and luciferase activity in lysates was determined using the Promega Firefly Luciferase Assay System on a Berthold centro LB960 luminometer.
- Analysis of NF-κB Nuclear Translocation via Confocal Microscopy.
- For confocal imaging, 105 HEK293-T cells/well (in 6-well plate) were seeded on glass coverslips (Zeiss), coated with poly-L-lysine (Sigma). The next day, cells were transfected with 200 ng/well of empty vector or HER2Δcyt expression plasmid using the calcium phosphate precipitation method. After 48 hours, cells were treated for 30 minutes with vehicle (medium) or IL1-Her2 nanobody fusion protein (10 ng/ml). Next, cells were rinsed with 1×PBS and fixed for 15 minutes at room temperature in 4% paraformaldehyde. After three washes with 1×PBS, cells were permeabilized with 0.1% Triton X-100 in 1×PBS for 10 minutes and blocked in 1% BSA in 1×PBS for another 10 minutes at room temperature. Samples were then incubated for 1 hour at 37° C. with rabbit anti-p65 antibody (Santa Cruz C20, diluted 1:800) and mouse anti-Flag Antibody (Sigma M2, 1:2000). After four washes in 1×PBS, cells were incubated for 1 hour at room temperature with anti-rabbit Alexa 488 and anti-mouse Alexa 594 fluorochrome-conjugated secondary antibodies (both diluted 1:800). After secondary antibody incubation, cells were washed four times in 1×PBS and nuclei were stained with DAPI (2 μg/ml). After a final wash step in 1×PBS, coverslips were mounted using propyl gallate. Images were acquired using a 60×1.35 NA objective on an Olympus IX-81 laser scanning confocal microscope and analyzed using Fluoview 1000 software.
-
FIG. 1 shows a scheme of the IL-1β-nanobody fusion proteins constructed with either WT hIL-1β or the hIL1β mutants described in table I. - Wild type IL-1β and 45 IL-1β mutants (Table I) were fused to a well-characterized nanobody recognizing Her2 (1 R59B). The IL-1β-nanobody fusion proteins were tested on HEK-Blue™ IL-1β cells, transiently transfected with an NF-κB reportergene plasmid (5 ng/well) and a Her2Δcyt (signalling-deficient) expression plasmid (2 ng/well). Cells were treated for 6 hours with IL-1β-Her2 nanobody fusions (dose response ranging from 0.4 to 250 ng/ml). As demonstrated in
FIG. 2A , the IL-1β-Q148G-Her2 nanobody fusion displayed a reduced ability to activate NF-κB as compared to the WT IL1-β-Her2 nanobody fusion. Importantly, targeting of the Q148G mutant to Her2Δcyt-expressing cells restored its activity and produced a dose-response curve for NF-κB activation that perfectly parallels that of the WT IL-1β on mock-transfected cells. Also evident from this figure is a strong targeting effect for the WT IL-1β Her2 nanobody fusion. Similar “activation by targeting” effects were observed for six other IL-1β mutants (R120G, Q131G, H146A, H145A/L147A, F162A/Q164E and K208E) fused to the Her2 nanobody (FIG. 2B ). - To obtain further proof for the “activation by targeting” concept, we next explored whether we could visualize the selective activation of NF-κB in Her2-expressing cells by the IL-1β-Her2 nanobody fusions via confocal microscopy. We measured activation of endogenous NF-
K B by assaying its nuclear translocation. As evident fromFIG. 3 , only the WT IL-1β-Her2 nanobody fusion promoted translocation of endogenous NF-κB in cells that do not express Her2. Whereas they did not promote detectable NF-κB translocation in mock-transfected cells, the three tested mutant IL1-β-Her2 nanobody fusions triggered NF-κB nuclear translocation in cells that also stained positive for Her2, indicating they only act on targeted cells. - To evaluate whether the “activation by targeting” concept also works using a nanobody to an unrelated membrane protein, we fused WT IL-1β and five of the disabled IL-1β mutants (R120G, Q131G, H146A, Q148G, K209A) to a previously characterized nanobody recognizing the mLR (4-10). An experiment similar to that reported for the IL-1β-Her2 nanobody fusion (
FIG. 2 ) was performed using HEK-Blue™ IL-1β cells, transiently transfected with a mLR expression plasmid (10 ng/well). Similar to the results obtained with the Her2 nanobody fusion proteins, all investigated mutant IL-1β nanobody fusions (tested at 12.5 ng/ml) showed a reduced ability, as compared to the WT fusion, to activate NF-κB on cells that do not express mLRs. However, targeting by the mLR nanobody moiety partially restored the activity of the selected mutants (FIG. 4 ). - Because the IL-1β mutants described above retained significant residual biological activity, we combined different mutations to obtain double/triple mutants with reduced basal activity. Nine double/triple mutants were tested (cf. table I mutants 46 to 54) and from these, six mutant proteins (Q131G/Q148G, Q148G/K208E, R120G/Q131G, R120G/Q131G, R120G/H146A, R120G/K208E, R120G/F162A/Q164E) displayed no residual activity (using the same assay for measuring NF-κB as in
FIG. 2 ) on Her2-negative cells, whilst partially restored activity was apparent on cells overexpressing Her2Δcyt (FIG. 5 ). - These data altogether indicate that targeting partially inactive mutant IL-1β, by fusing it to a nanobody recognizing a cell surface receptor, can restore its activity on nanobody target cells, probably by forced receptor interaction through a membrane concentration effect. The fact that activation by targeting can be accomplished using nanobodies recognizing different classes of membrane proteins indicates broad applicability of the “activation by targeting” concept.
- Because these data provide proof of concept for the ability of targeting mutant IL-1 family members to selected cell types, restoring their activity on these target cells only, nanobodies are produced that allow targeting IL-1 family members to physiologically relevant IL-1β target cells. In view of the important role of IL-1 family members as T- and NK-cell activators, the nanobodies are designed to specifically target IL-1 to T- and NK-cell subsets. More specifically nanobodies targeting CCR6, which are predominantly expressed on Th17 cells as well as nanobodies targeting CD8 on cytotoxic T cells are developed and fused to the members of the IL1-family, preferably IL-1β.
- Primary human T cells were isolated from buffy coats. First, PBMC's were isolated by lymphoprep density gradient centrifugation and incubated O/N with 0.5 ng/ml rhIL-2 for recovery. Next, T-cells were isolated using the pan-T cell isolation kit (Miltenyi Biotec) according to the manufacturer's instructions. Briefly, T cells were resuspended (1×106/ml) in RPMI-1640 supplemented with 10% FCS and CD3/CD28 activating microbeads (Miltenyi Biotec). Next, cells (100 μl/well) were plated in U-bottom 96-well plates and stimulated for 96 hours with the indicated concentrations of IL-1β variants. After an additional 6 hours stimulation with PMA/ionomycin (both at 100 nM), supernatants were recovered and IL-17 levels were determined by Elisa (R&D Systems). Additional cytokines are evaluated via Luminex technology.
- For selected mutant IL-1β-nanobody fusions (e.g. with a nanobody targeting CCR6) target cell-specific IL-17 and IFNγ production are evaluated by intracellular staining using a flow cytometric approach.
- Also, to corroborate selectivity for the Th17 population, binding to PBMC subpopulations is measured via double staining using the Flag tag and selected CD markers, followed by flow cytometric analysis.
- Finally, in a clinically relevant in vitro model of human Th17 cell function, the adjuvant activity of the IL-1β-nanobody fusions is assessed. In view of the need for more efficacious vaccines against Bordetella pertussis (or adjuvants for the existing vaccines), we determined whether the selected fusion proteins enhance the human Th17 response in a coculture model of naïve T cells with B. pertussis-treated monocyte-derived dendritic cells (MDDCs). Human MDDCs are isolated from buffy coats (using the monocyte isolation kit II, Miltenyi Biotec), treated with different ratios of B. pertussis for 48 hours and then cocultured with naïve allogeneic T cells for 12 days. After restimulation with anti-CD3/anti-CD28, the cytokine profiles in supernatants are determined using Elisa/Luminex technology (cfr. supra).
- To assess whether IL-1β-CD8 nanobody fusions can specifically enhance the function of CD8+ T cells, human PBMC's are isolated by lymphoprep density gradient centrifugation from buffy coats and stimulated for 24 hours with CD3/CD28 activating microbeads (Miltenyi Biotec) in combination with wt or mutant IL1β-CD8 Nb fusions. The effect of these fusion proteins on CD8+ T cell activation is evaluated by performing intracellular staining for active (phosphorylated) NF-κB and IFNγ. In addition, to investigate whether the IL-1β-nanobody fusions affect CTL degranulation, PBMC's (2×106 cells/ml) are differentiated for 48 hours in the presence of phytohaemagglutinin (PHA, 1 μg/ml) and IL-2 (100 IU/ml) in combination with increasing doses of the IL-1β fusion proteins. Next, to induce degranulation, cells are stimulated for 3 hours with CD3/CD28 dynabeads and analysed by flow cytometry. Degranulation is measured via detection of cell surface CD107a, a well-established marker for natural killer activity. In all flow cytometric analyses on leukocyte pools, anti-CD8 staining is included to allow monitoring of the cell-type specificity of the IL-1β-CD8 Nb effects.
- Finally to assess whether the IL-1β-CD8 nanobody fusions promote anti-tumor activity in vivo, C57BL/6 mice are injected subcutaneously with TC1 tumor cells, which produce the E6 and E7 antigenic oncoproteins from HPV16. This model was previously used to demonstrate that IL-1β promotes CD8+ T cell-mediated, antigen-specific, anti-tumor responses (Ben-Sasson, 2013). Briefly, mice are immunized four days after tumor injection with a vaccine containing the HPV16E749-57 peptide, combined with DOTAP and LPS, and with our without WT or mutant IL-1β-CD8 Nb fusions or IL-1β-GFP Nb fusions. Tumor size is monitored for 18 days post-immunization.
- In a first series of experiments C57BL/6 mice are treated iv/ip with different doses of WT and mutant IL-1β-nanobody fusions and unfused IL-1β, to monitor acute toxicity. Venous blood is collected at different times post treatment by tail venopuncture and the cytokine profile in serum is determined by Luminex assay. In addition, via flow cytometric analysis intracellular cytokine levels (IL-17, IFNγ) and activation of IL-1R (as assessed by measuring phospho-NF-κB levels) are determined in selected leukocyte subsets.
- When optimal doses have been established, their adjuvant activity is assessed in a murine vaccination protocol. Briefly, C57BL/6 mice are immunized ip with acellular pertussis vaccine (Pa). The Pa vaccine is composed of 5 μg/mouse of purified recombinant detoxified pertussis toxin (PT9K/129G)+filamentous hemagglutinin (FHA) (composition according to Brereton et al., 2011). 24 hours after immunization, selected mutant IL1β-Nb or PBS are administered ip or iv. Animals are boosted after 28 days. One set of animals is sacrificed 14 days after the second immunization and splenocytes are isolated and restimulated in vitro with medium or FHA for 3 days. Cytokine levels in culture supernatants (IL-17, IFNγ, IL-2, IL-10, IL-5, IL-4, etc.) are determined via Luminex technology. A second set of mice is challenged with B. pertussis on day 14 post-boost and sacrificed 2 h and 5 and 10 days post-challenge. Lungs are isolated and CFU in lung homogenates will be quantified on Bordet-Gengou agar plates. Cytokine levels in lung homogenates are determined as in splenocyte supernatants.
- In addition, blood is sampled (from the tail vene) before immunization and then every 14 days for determination of B. pertussis-specific IgG levels in serum.
- To investigate the direct anti-tumour activity of selected IL1-nanobody fusions, we use human A375 melanoma cells, which were shown to be highly susceptible to IL-1-induced cytostatic effects (Morinaga et al., 1990). To allow targeting of mutant IL-1 family members to the A375 cells, a stable A375 clone expressing a cell surface marker to which high-affinity nanobodies are already available (i.e. CD20) is generated. The sensitivity of this cell line, as compared to the parental A375 cells, to the antiproliferative effect of the mutant IL1-nanobody fusion, is investigated in vitro using the XTT proliferation assay. In vivo anti-tumour activity of the mutant IL-1-nanobody fusions is investigated using an A375 xenotransplant model. Briefly, athymic nude mice are inoculated subcutaneously with A375 cells (parental or expressing a surface marker for targeting) and tumor growth is monitored for four weeks in animals treated with PBS or mutant IL1-nanobody fusions.
- To assess the indirect anti-tumour activity of IL1 family members, experiments are conducted to address the efficacy of selected mutant IL-18-nanobody fusions using the Meth A syngeneic mouse sarcoma model according to the protocol that was used previously to demonstrate anti-tumour activity of IL-18 (Micallef et al., 1997). IL18 variants used in these experiments consist of mutant IL-18s fused to nanobodies targeting immune cells with tumoricidal properties (i.e. CTLs, NK-cells). The mice are treated with the construct, and a significant reduction of the tumor is noted when compared to the mock treated control.
- Acosta-Rodriguez E V, Napolitani G, Lanzavecchia A, Sallusto F. (2007) Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol. 8:942-9.
- Allakhverdi Z, Smith D E, Comeau M R, Delespesse G. (2007) Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol. 179:2051-4.
- Ben-Sasson S Z, Caucheteux S, Crank M, Hu-Li J, Paul W E. (2011) IL-1 acts on T cells to enhance the magnitude of in vivo immune responses. Cytokine.56:122-5.
- Ben-Sasson S Z, Hogg A, Hu-Li J, Wingfield P, Chen X, Crank M, Caucheteux S, Ratner-Hurevich M, Berzofsky J A, Nir-Paz R, Paul W E. (2013) IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. J Exp Med. 210:491-502.
- Blake, A. W., McCartney, L., Flint, J., Bolam, D. N., Boraston, A. B., Gilbert, H. J. and Knox, J. P. (2006) Understanding the biological rationale for the diversity of cellulose-directed carbohydrate-binding molecules in prokaryotic enzymes. J. Biol. Chem. 281, 29321-29329.
- Bonilla W V, Fröhlich A, Senn K, Kallert S, Fernandez M, Johnson S, Kreutzfeldt M, Hegazy A N, Schrick C, Fallon P G, Klemenz R, Nakae S, Adler H, Merkler D, Löhning M, Pinschewer D D. (2012). The alarmin interleukin-33 drives protective antiviral CD8+ T cell responses. Science. 335:984-9.
- Brecht A., Gauglitz G., Polster J. (1993). Interferometric immunoassay in a FIA-system—A sensitive and rapid approach in label-free immunosensing. Biosens Bioelectron 8: 387-392.
- Brereton C F, Sutton C E, Ross P J, Iwakura Y, Pizza M, Rappuoli R, Lavelle E C, Mills K H. (2011). Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production. J Immunol. 2011 May 15; 186(10):5896-906.
- Dimitrov, D. S. (2009) Engineered CH2 domains (nanoantibodies).
mAbs 1, 26-28. - Dinarello C A, Simon A, van der Meer J W. (2012). Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 11:633-52.
- Dunne A, Ross P J, Pospisilova E, Masin J, Meaney A, Sutton C E, Iwakura Y, Tschopp J, Sebo P, Mills K H. (2010). Inflammasome activation by adenylate cyclase toxin directs Th17 responses and protection against Bordetella pertussis. J Immunol. 185:1711-9.
- Higgins S C, Jarnicki A G, Lavelle E C, Mills K H. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol. 2006 Dec. 1; 177(11):7980-9.
- Khader S A, Bell G K, Pearl J E, Fountain J J, Rangel-Moreno J, Cilley G E, Shen F, Eaton S M, Gaffen S L, Swain S L, Locksley R M, Haynes L, Randall T D, Cooper A M. (2007). IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol. 2007 8:369-77.
- Killar, L. M., Hatfield, C. A., Carding, S. R., Pan, M., Winterrowd, G. E. and Bottomly, K. (1989) In vivo administration of
interleukin 1 elecits an increased la antigen expression on B cells throught the production ofinterleukin 4. Eur. J. Immunol. 19, 2205-2210. - Kinoshita, M., Miyazaki, H., Ono, S., Inatsu, A., Nakashima, H., Tsujimoto, H., Shinomiya, N., Saitoh, D. and Seki, S. (2011). Enhancement of neutrophil function by interleukin 18 therapy protects burn-injuredf mice from methicillin-resistant Staphylococcus aureus. Infect. Immun. 79, 2670-2680.
- Kolmar, H. (2008) Alternative binding proteins: biological activity and therapeutic potential of cysteine-knot miniproteins. FEBS J. 275, 2684-2690.
- Leung B P, Culshaw S, Gracie J A, Hunter D, Canetti C A, Campbell C, Cunha F, Liew F Y, McInnes I B. (2001). A role for IL-18 in neutrophil activation. J Immunol. 167:2879-86.
- Loeffler M, Le'Negrate G, Krajewska M, Reed J C. (2008). IL-18-producing Salmonella inhibit tumor growth. Cancer Gene Ther. 15:787-94.
- Micallef M J, Tanimoto T, Kohno K, Ikeda M, Kurimoto M. (1997). Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res. ; 57:4557-63.
- Morinaga Y, Hayashi H, Takeuchi A, Onozaki K. (1990). Antiproliferative effect of interleukin 1 (IL-1) on tumor cells: G0-G1 arrest of a human melanoma cell line by IL-1. Biochem Biophys Res Commun. 173:186-92.
- Nygren, P-A. (2008) Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J. 275, 2668-2676.
- Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, et al. (1995). Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 378:88-91.
- Rangnekar V V, Waheed S, Rangnekar V M. (1992). Interleukin-1-inducible tumor growth arrest is characterized by activation of cell type-specific “early” gene expression programs. J Biol Chem. 267:6240-8.
- Robertson M J, Kirkwood J M, Logan T F, Koch K M, Kathman S, Kirby L C, Bell W N, Thurmond L M, Weisenbach J, Dar M M. (2008). A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res. 14:3462-9
- Scatchard G. (1949). Ann New York Acad Sci 51, 660-72.
- Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan T K, Zurawski G, Moshrefi M, Qin J, Li X, Gorman D M, Bazan J F, Kastelein R A. (2005). IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 23:479-90.
- Shaw M H, Kamada N, Kim Y G, Núñez G. (2012). Microbiota-induced IL-1β, but not IL-6, is critical for the development of steady-state TH17 cells in the intestine. J Exp Med. 209:251-8.
- Sims J E, Smith D E. The IL-1 family: regulators of immunity. (2010). Nat Rev Immunol. 10:89-102.
- Skerra, A. (2008) Alternative binding proteins: anticalins—harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J. 275, 2677-2683.
- Stump, M. T., Binz, H. K., Amstutz, P. (2008) DARPins: a new generation of protein therapeutics. Drug iscov. Today 13, 695-701.
- Sutton C, Brereton C, Keogh B, Mills K H, Lavelle E C. (2006). A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med. 203:1685-91.
- Takeda K, Tsutsui H, Yoshimoto T, Adachi O, Yoshida N, Kishimoto T, Okamura H, Nakanishi K, Akira S. (1998). Defective NK cell activity and Th1 response in IL-18-deficient mice.
- Immunity. 8:383-90.
- Tramontano, A., Bianchi, E., Venturini, S., Martin, F., Pessi, A and Sollazzo, M. (1994) The making of the minibody: an engineered beta-protein for the display of conformationally constrained peptides. J. Mol. Recognition 7, 9-24.
- Usui N, Mimnaugh E G, Sinha B K. (1991). A role for the
interleukin 1 receptor in the synergistic antitumor effects ofhuman interleukin 1 alpha and etoposide against human melanoma cells. Cancer Res. 1991 51:769-74. - Vanden Berghe W, Plaisance S, Boone E, De Bosscher K, Schmitz M L, Fiers W, Haegeman G. (1998). p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J Biol Chem. 273:3285-90.
- Vaneycken I, Devoogdt N, Van Gassen N, Vincke C, Xavier C, Wernery U, Muyldermans S, Lahoutte T, Caveliers V. (2011). Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J. 25:2433-46.
- Wigginton J M, Lee J K, Wiltrout T A, Alvord W G, Hixon J A, Subleski J, Back T C, Wiltrout R H. (2002). Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-gamma and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2. J Immunol. 169:4467-74.
- Wilke C M, Bishop K, Fox D, Zou W. (2011). Deciphering the role of Th17 cells in human disease. Trends Immunol. 32:603-11.
- Ye P, Rodriguez F H, Kanaly S, Stocking K L, Schurr J, Schwarzenberger P, Oliver P, Huang W, Zhang P, Zhang J, Shellito J E, Bagby G J, Nelson S, Charrier K, Peschon J J, Kolls J K. (2001). Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med. 194:519-27.
- Zabeau L, Verhee A, Catteeuw D, Faes L, Seeuws S, Decruy T, Elewaut D, Peelman F, Tavernier J. (2012). Selection of non-competitive leptin antagonists using a random nanobody-based approach. Biochem J. 441:425-34.
- Zaki M H, Vogel P, Body-Malapel M, Lamkanfi M, Kanneganti TD. (2010). IL-18 production downstream of the NIrp3 inflammasome confers protection against colorectal tumor formation. J Immunol. 185:4912-20.
Claims (13)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/901,545 US20180186894A1 (en) | 2013-07-19 | 2018-02-21 | Targeted modified il-1 family members |
US16/360,793 US20190202934A1 (en) | 2013-07-19 | 2019-03-21 | Targeted modified il-1 family members |
US16/860,660 US20200255545A1 (en) | 2013-07-19 | 2020-04-28 | Targeted modified il-1 family members |
US18/163,026 US20230235086A1 (en) | 2013-07-19 | 2023-02-01 | Targeted modified il-1 family members |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13306047.5 | 2013-07-19 | ||
EP13306047 | 2013-07-19 | ||
PCT/EP2014/064283 WO2015007542A1 (en) | 2013-07-19 | 2014-07-04 | Targeted modified il-1 family members |
US201614905352A | 2016-01-15 | 2016-01-15 | |
US15/901,545 US20180186894A1 (en) | 2013-07-19 | 2018-02-21 | Targeted modified il-1 family members |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/064283 Continuation WO2015007542A1 (en) | 2013-07-19 | 2014-07-04 | Targeted modified il-1 family members |
US14/905,352 Continuation US9932409B2 (en) | 2013-07-19 | 2014-07-04 | Targeted modified IL-1 family members |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/360,793 Continuation US20190202934A1 (en) | 2013-07-19 | 2019-03-21 | Targeted modified il-1 family members |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180186894A1 true US20180186894A1 (en) | 2018-07-05 |
Family
ID=48874235
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/905,352 Active US9932409B2 (en) | 2013-07-19 | 2014-07-04 | Targeted modified IL-1 family members |
US15/901,545 Abandoned US20180186894A1 (en) | 2013-07-19 | 2018-02-21 | Targeted modified il-1 family members |
US16/360,793 Abandoned US20190202934A1 (en) | 2013-07-19 | 2019-03-21 | Targeted modified il-1 family members |
US16/860,660 Abandoned US20200255545A1 (en) | 2013-07-19 | 2020-04-28 | Targeted modified il-1 family members |
US18/163,026 Pending US20230235086A1 (en) | 2013-07-19 | 2023-02-01 | Targeted modified il-1 family members |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/905,352 Active US9932409B2 (en) | 2013-07-19 | 2014-07-04 | Targeted modified IL-1 family members |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/360,793 Abandoned US20190202934A1 (en) | 2013-07-19 | 2019-03-21 | Targeted modified il-1 family members |
US16/860,660 Abandoned US20200255545A1 (en) | 2013-07-19 | 2020-04-28 | Targeted modified il-1 family members |
US18/163,026 Pending US20230235086A1 (en) | 2013-07-19 | 2023-02-01 | Targeted modified il-1 family members |
Country Status (14)
Country | Link |
---|---|
US (5) | US9932409B2 (en) |
EP (1) | EP3022226B1 (en) |
JP (1) | JP6475713B2 (en) |
KR (1) | KR102275090B1 (en) |
CN (1) | CN105612180B (en) |
AU (1) | AU2014292377B2 (en) |
BR (1) | BR112016001128A2 (en) |
CA (1) | CA2918518C (en) |
DK (1) | DK3022226T3 (en) |
ES (1) | ES2714504T3 (en) |
IL (1) | IL243466B (en) |
MX (1) | MX370348B (en) |
SG (1) | SG11201600167SA (en) |
WO (1) | WO2015007542A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10906985B2 (en) | 2017-02-06 | 2021-02-02 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
US11384154B2 (en) | 2017-02-06 | 2022-07-12 | Orionis Biosciences BV | Targeted chimeric proteins and uses thereof |
US11440943B2 (en) | 2019-03-28 | 2022-09-13 | Orionis Biosciences, Inc. | Therapeutic interferon alpha 1 proteins |
US11498966B2 (en) | 2017-08-09 | 2022-11-15 | Orionis Biosciences Inc. | PD-1 and PD-L1 binding agents |
US11566072B2 (en) | 2017-08-09 | 2023-01-31 | Orionis Biosciences, Inc. | CD8 binding agents |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10508143B1 (en) | 2015-10-30 | 2019-12-17 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
EP3368077A4 (en) | 2015-10-30 | 2019-10-16 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
EP3371311B1 (en) | 2015-11-06 | 2021-07-21 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
CN115850521A (en) | 2016-02-05 | 2023-03-28 | 奥里尼斯生物科学私人有限公司 | Targeted therapeutic agents and uses thereof |
WO2017153402A1 (en) | 2016-03-07 | 2017-09-14 | Vib Vzw | Cd20 binding single domain antibodies |
EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
JP7105200B2 (en) | 2016-05-13 | 2022-07-22 | オリオニス バイオサイエンシズ ビーブイ | Targeted mutant interferon-beta and its uses |
US11753463B2 (en) | 2016-05-13 | 2023-09-12 | Orionis Biosciences BV | Therapeutic targeting of non-cellular structures |
US11084859B2 (en) | 2016-10-24 | 2021-08-10 | Orionis Biosciences BV | Targeted mutant interferon-gamma and uses thereof |
US11246911B2 (en) | 2017-02-07 | 2022-02-15 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
JP2020511528A (en) * | 2017-03-03 | 2020-04-16 | オブシディアン セラピューティクス, インコーポレイテッド | Compositions and methods for immunotherapy |
EP3638697A4 (en) | 2017-06-12 | 2021-07-07 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
WO2019152979A1 (en) | 2018-02-05 | 2019-08-08 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
CA3185087A1 (en) * | 2020-07-07 | 2022-01-13 | Nikolai Kley | Immunostimulatory adjuvants |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2055445T3 (en) | 1989-08-22 | 1994-08-16 | Immunex Corp | FUSION PROTEINS INCLUDING GM-CSF AND IL-3. |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US5914254A (en) * | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
AU1215801A (en) * | 1999-10-21 | 2001-04-30 | Sarnoff Corporation | Bi-potential electrode space-saving cathode ray tube |
CA2585549A1 (en) | 2004-11-18 | 2006-05-26 | Vib Vzw | Novel type leptin receptor antagonist |
WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
US7947265B2 (en) | 2006-08-02 | 2011-05-24 | Mcgill University | Fusion proteins and methods for modulation of immune response |
WO2008124086A2 (en) * | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
WO2009003145A1 (en) * | 2007-06-26 | 2008-12-31 | University Of Miami | Antibody-endostatin fusion protein and its variants |
ES2536772T3 (en) | 2007-09-21 | 2015-05-28 | The Regents Of The University Of California | Targeted interferon demonstrates potent apoptotic and antitumor activities |
WO2010036918A2 (en) | 2008-09-26 | 2010-04-01 | University Of Massachusetts | Intracellular dna receptor |
CN102245623A (en) | 2008-12-08 | 2011-11-16 | 康普里斯有限公司 | Single-chain antiparallel coiled coil proteins |
KR101588598B1 (en) * | 2009-08-17 | 2016-01-29 | 로슈 글리카트 아게 | Targeted immunoconjugates |
CN102497885A (en) * | 2009-09-10 | 2012-06-13 | 赛托斯生物技术公司 | Use of interleukin-1 beta mutein conjugates in the treatment of diabetes |
EP2718457A4 (en) | 2011-06-06 | 2014-12-24 | Immungene Inc | Engineered antibody-tnfsf member ligand fusion molecules |
CN109022465B (en) | 2011-10-28 | 2022-04-29 | 特瓦制药澳大利亚私人有限公司 | Polypeptide constructs and uses thereof |
CA2861927C (en) | 2012-01-20 | 2021-01-26 | Vib Vzw | Targeted mutant alpha-helical bundle cytokines |
WO2013134138A1 (en) | 2012-03-03 | 2013-09-12 | Immungene, Inc. | Engineered antibody-interferon mutant fusion molecules |
-
2014
- 2014-07-04 ES ES14735574T patent/ES2714504T3/en active Active
- 2014-07-04 AU AU2014292377A patent/AU2014292377B2/en active Active
- 2014-07-04 MX MX2016000723A patent/MX370348B/en active IP Right Grant
- 2014-07-04 CN CN201480040652.6A patent/CN105612180B/en active Active
- 2014-07-04 KR KR1020167002679A patent/KR102275090B1/en active IP Right Grant
- 2014-07-04 WO PCT/EP2014/064283 patent/WO2015007542A1/en active Application Filing
- 2014-07-04 SG SG11201600167SA patent/SG11201600167SA/en unknown
- 2014-07-04 EP EP14735574.7A patent/EP3022226B1/en active Active
- 2014-07-04 JP JP2016526518A patent/JP6475713B2/en active Active
- 2014-07-04 BR BR112016001128-7A patent/BR112016001128A2/en not_active Application Discontinuation
- 2014-07-04 US US14/905,352 patent/US9932409B2/en active Active
- 2014-07-04 CA CA2918518A patent/CA2918518C/en active Active
- 2014-07-04 DK DK14735574.7T patent/DK3022226T3/en active
-
2016
- 2016-01-05 IL IL24346616A patent/IL243466B/en active IP Right Grant
-
2018
- 2018-02-21 US US15/901,545 patent/US20180186894A1/en not_active Abandoned
-
2019
- 2019-03-21 US US16/360,793 patent/US20190202934A1/en not_active Abandoned
-
2020
- 2020-04-28 US US16/860,660 patent/US20200255545A1/en not_active Abandoned
-
2023
- 2023-02-01 US US18/163,026 patent/US20230235086A1/en active Pending
Non-Patent Citations (1)
Title |
---|
Daniels et al. Critical Role for CD8 in T Cell Receptor Binding and Activation by Peptide/Major Histocompatibility Complex Multimers. J. Exp. Med., 2000, 191 (2): 335-346. * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10906985B2 (en) | 2017-02-06 | 2021-02-02 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
US11384154B2 (en) | 2017-02-06 | 2022-07-12 | Orionis Biosciences BV | Targeted chimeric proteins and uses thereof |
US11498966B2 (en) | 2017-08-09 | 2022-11-15 | Orionis Biosciences Inc. | PD-1 and PD-L1 binding agents |
US11566072B2 (en) | 2017-08-09 | 2023-01-31 | Orionis Biosciences, Inc. | CD8 binding agents |
US11440943B2 (en) | 2019-03-28 | 2022-09-13 | Orionis Biosciences, Inc. | Therapeutic interferon alpha 1 proteins |
Also Published As
Publication number | Publication date |
---|---|
KR102275090B1 (en) | 2021-07-09 |
CA2918518A1 (en) | 2015-01-22 |
BR112016001128A2 (en) | 2018-01-23 |
CN105612180B (en) | 2019-11-12 |
US20200255545A1 (en) | 2020-08-13 |
SG11201600167SA (en) | 2016-02-26 |
EP3022226A1 (en) | 2016-05-25 |
US20230235086A1 (en) | 2023-07-27 |
JP6475713B2 (en) | 2019-02-27 |
KR20160108293A (en) | 2016-09-19 |
US20190202934A1 (en) | 2019-07-04 |
AU2014292377A1 (en) | 2016-02-04 |
CA2918518C (en) | 2022-08-16 |
US9932409B2 (en) | 2018-04-03 |
MX2016000723A (en) | 2016-12-20 |
ES2714504T3 (en) | 2019-05-28 |
DK3022226T3 (en) | 2019-03-25 |
JP2016527221A (en) | 2016-09-08 |
EP3022226B1 (en) | 2018-12-05 |
CN105612180A (en) | 2016-05-25 |
WO2015007542A1 (en) | 2015-01-22 |
US20160152730A1 (en) | 2016-06-02 |
MX370348B (en) | 2019-12-10 |
AU2014292377B2 (en) | 2019-08-01 |
IL243466A0 (en) | 2016-03-31 |
IL243466B (en) | 2019-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230235086A1 (en) | Targeted modified il-1 family members | |
US11028166B2 (en) | Albumin binding domain fusion proteins | |
US7723299B2 (en) | Methods for treating rheumatoid arthritis using a CTLA-4 fusion protein | |
CA3082904A1 (en) | Partial agonists of interleukin-2 | |
JP2021534823A (en) | Anti-BCMA single domain antibody and its application | |
CN110392695A (en) | For the antibody and polypeptide of CD127 | |
CN108350032A (en) | Adjust γ C- cytokine activities | |
JP5012926B2 (en) | IL-6 receptor / IL-6 direct fusion protein | |
JP2021527047A (en) | BTNL3 / 8 targeting construct for payload delivery to the gastrointestinal system | |
WO2022190008A1 (en) | Protease cleavable prodrugs | |
JP2022508619A (en) | Methods of Using Neuromedin Peptides to Reduce Type 2 Cytokine-mediated Inflammation | |
JPWO2005023853A1 (en) | Protease resistant SEB variant and vaccine comprising the same | |
CN111100211B (en) | Fc fusion protein and application thereof | |
JP4524816B2 (en) | IL-6 receptor / IL-6 direct fusion protein | |
CN117242094A (en) | Protease cleavable prodrugs | |
KR20130011056A (en) | Receptors targeting inflammation and drug carriers for treatment of inflammatory diseases | |
JP2001526893A (en) | TIGIRR DNA and polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: UNIVERSITEIT GENT, BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAVERNIER, JAN;GERLO, SARAH;PEELMAN, FRANK;AND OTHERS;SIGNING DATES FROM 20160318 TO 20160323;REEL/FRAME:046098/0499 Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FRAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAVERNIER, JAN;GERLO, SARAH;PEELMAN, FRANK;AND OTHERS;SIGNING DATES FROM 20160318 TO 20160323;REEL/FRAME:046098/0499 Owner name: VIB VZW, BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAVERNIER, JAN;GERLO, SARAH;PEELMAN, FRANK;AND OTHERS;SIGNING DATES FROM 20160318 TO 20160323;REEL/FRAME:046098/0499 Owner name: UNIVERSITE MONTPELLIER 2, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAVERNIER, JAN;GERLO, SARAH;PEELMAN, FRANK;AND OTHERS;SIGNING DATES FROM 20160318 TO 20160323;REEL/FRAME:046098/0499 Owner name: UNIVERSITE DE MONTPELLIER, FRANCE Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:UNIVERSITE MONTPELLIER 2;UNIVERSITE DE MONTPELLIER;REEL/FRAME:046374/0836 Effective date: 20140911 Owner name: UNIVERSITE DE MONTPELLIER, FRANCE Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:UNIVERSITE MONTPELLIER 2;UNIVERSITE DE MONTPELLIER;REEL/FRAME:046376/0371 Effective date: 20140911 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |